RYTM FY 2023 Earnings — Rhythm Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

RYTMRhythm Pharmaceuticals, Inc.

$6B

FY 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$77M+227.6% YoY

Gross Profit

$68M88.0% margin

Operating Income

-$184M-238.1% margin

Net Income

-$185M-238.5% margin

EPS (Diluted)

$-3.20

Cash Flow

Operating Cash Flow

-$136M

Free Cash Flow

-$136M

Stock-Based Comp.

$33M

Balance Sheet

Total Assets

$333M

Total Liabilities

$163M

Stockholders' Equity

$170M

Cash & Equivalents

$60M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$77M	$24M	+227.6%
Gross Profit	$68M	$22M	+216.8%
Operating Income	-$184M	-$179M	-2.9%
Net Income	-$185M	-$181M	-2.0%